BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 11.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,928,094 shares of the medical technology company’s stock after buying an additional 297,850 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 2.07% of Alphatec worth $16,280,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. ProShare Advisors LLC boosted its holdings in shares of Alphatec by 8.5% in the first quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company’s stock worth $229,000 after acquiring an additional 1,304 shares during the period. Vanguard Group Inc. grew its holdings in Alphatec by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 5,458,847 shares of the medical technology company’s stock valued at $75,278,000 after buying an additional 64,648 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Alphatec by 14.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,346 shares of the medical technology company’s stock valued at $364,000 after buying an additional 3,268 shares in the last quarter. Bayesian Capital Management LP increased its position in shares of Alphatec by 5.6% during the first quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company’s stock valued at $372,000 after buying an additional 1,442 shares during the period. Finally, Comerica Bank lifted its holdings in shares of Alphatec by 64.8% in the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after buying an additional 2,534 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Down 1.5 %

Shares of ATEC opened at $10.06 on Friday. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The stock has a 50 day simple moving average of $6.71 and a two-hundred day simple moving average of $8.27. The firm has a market cap of $1.43 billion, a P/E ratio of -7.86 and a beta of 1.31.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 target price on shares of Alphatec in a report on Thursday, October 31st. Piper Sandler dropped their price objective on Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 30th. Morgan Stanley downgraded Alphatec from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Finally, Lake Street Capital decreased their price objective on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Alphatec has a consensus rating of “Moderate Buy” and a consensus price target of $17.11.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.